IP Library Granted Patent US 9,139,830
Granted Patent B2
US 9,139,830 · App. 13/916,699 · Granted Sep 22, 2015

Methods and compositions for inducing deregulation of EPHA7 and ERK phosphorylation in human acute leukemias

Inventor: Carlo M. Croce (Columbus, OH)
Assignee: The Ohio State University Research Foundation
C12N15/113C12N15/1138C12Q1/6886G01N33/5041G01N33/57426G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,139,830
App. No.
13/916,699
Granted
Sep 22, 2015
Kind
B2
Abstract

Methods for assessing a pathological condition in a subject include measuring one or more markers where a difference is indicative of acute lymphoblastic leukemia (ALL) or a predisposition to ALL, uses and compositions are disclosed.

Claims (7)

1. A method to interfere with an acute lymphoblastic leukemia (ALL) response signaling pathway in at least one leukemic cell producing an ALL1/AF9 chimeric fusion protein, wherein the method comprises:

administering, to at least one K562 leukemic cell, 5-iodotubericidin and an ALL1/AF9-specific siRNA consisting of “SEMj” which suppresses expression of an ALL1/AF9 chimeric fusion protein, thereby interfering with an acute lymphoblastic leukemia (ALL) response signaling pathway.

2. The method of claim 1 , wherein the at least one leukemic cell is in a living organism.

3. The method of claim 2 , wherein the organism is a human.

4. A method to interfere with an acute lymphoblastic leukemia (ALL) response signaling pathway in at least one leukemic cell producing an ALL1/AF9 chimeric fusion protein,

comprising administering to at least one leukemic cell, 5-iodotubercidin and an ALL1/AF9-specific siRNA which suppresses expression of an ALL1/AF9 chimeric fusion protein, thereby interfering with an acute lymphoblastic leukemia (ALL) response signaling pathway.

5. The method of claim 4 , wherein the ALL1/AF9-specific siRNA is a SEMj siRNA.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 17, 2015
From: OHIO STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037121/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2013
From: CROCE, CARLO M.
To: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 030604/0464 →
Continuity (3)
Division 12674546
Provisional Application 60965757 · Aug 22, 2007
Related Publication 20130267579A1 · Oct 10, 2013